188.01 0.00 (0.00%)
After hours: 5:51PM EST
|Bid||172.90 x 100|
|Ask||191.00 x 500|
|Day's Range||185.90 - 189.30|
|52 Week Range||150.38 - 191.10|
|PE Ratio (TTM)||16.98|
|Forward Dividend & Yield||5.28 (2.85%)|
|1y Target Est||N/A|
While most investors tend to think of biotech stocks as pure lotto tickets, the reality is the sector is much more nuanced than that. Sure, there are bootstrapped, clinical-stage biotech stocks with only one potential drug in their arsenal.
How Is Amgen Positioned for 2018? In January 2018, the FDA approved Amgen’s (AMGN) supplemental Biologics License Application (or sBLA) for Xgeva. Xgeva is used for the prevention of skeletal-related events in individuals with bone metastasis from solid tumors.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.
This article is a part of InvestorPlace’s Best ETFs for 2018 contest. Johnson Research Group’s pick for the contest is the SPDR S&P Biotech (ETF) (NYSEARCA:XBI). 2018 has gotten off to a roaring start, and biotechnology stocks are no exception.
Amgen Inc (NASDAQ:AMGN), a large-cap worth $134.32B, comes to mind for investors seeking a strong and reliable stock investment. Risk-averse investors who are attracted to diversified streams of revenue andRead More...
Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.
The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.
Australia earlier this month joined the growing list of nations that have legalized medical marijuana. The Marijuana Index is a series of equally weighted stock indexes that track the leading cannabis stocks in the U.S. and Canada. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with a market cap of $3.34 billion, produces a multiple sclerosis treatment using nabiximols, an herbal preparation containing a defined quantity of specific cannabinoids with potential analgesic activity.